Report Overview

India Oncology Drugs Market – Industry Trends & Forecast Report, 2030

The India Oncology Drugs Market size was estimated at USD 2.18 billion in 2023. During the forecast period between 2024 and 2030, the India Oncology Drugs Market size is projected to grow at a CAGR of 7.89% reaching a value of USD 3.75 billion by 2030. Prominent drivers of the market are increasing awareness regarding cancer and its treatments, escalating disposable incomes, and enhanced healthcare accessibility. The rapid expansion of India's oncology drug market necessitates innovative solutions due to increasing cancer incidence, patient numbers, and adoption of novel therapies. With an estimated 1.4 million new cancer cases projected for 2020, the country faces a rising public health challenge. However, over 80% of patients present with advanced disease, highlighting issues with awareness, accessibility, and affordability. Private hospitals cater to 60% to 75% of cancer patients, but they often encounter high out-of-pocket costs and financial strain. By 2025, India's cancer burden is expected to surpass 1.5 million cases.

Oncology Drugs – Overview

Oncology drugs refer to pharmaceutical substances specifically designed to diagnose, treat, or manage various types of cancer. These drugs can include chemotherapy agents, targeted therapies, immunotherapies, hormone therapies, and supportive care medications. They are developed to interfere with the growth and spread of cancer cells or to alleviate symptoms associated with cancer or its treatment. Oncology drugs are typically prescribed by healthcare professionals, such as oncologists, and are an essential component of cancer treatment regimens aimed at improving patient outcomes and quality of life.

India Oncology Drugs Market

Growth Drivers

Rising Cancer Burden

As cancer prevalence escalates, accessibility to life-saving treatments grows alongside the affordability of medications. India's healthcare sector sees heightened interest from foreign investors due to the expanding oncology drug market. The NPPA's introduction of a Pilot on Trade Margin Rationalization for 42 anti-cancer drugs reflects a proactive stance to aid patients in affording crucial medical care. This trend prompts Indian pharmaceutical companies to focus notably on acquiring anticancer medications. Legislative calls for free cancer treatment for middle-class households highlight the urgency to address the mounting burden of cancer care.

Government Initiatives for Improving Cancer Care

India's response to the escalating cancer burden includes strategic governmental interventions. Notably, the NPPA's Pilot on Trade Margin Rationalization for 42 anti-cancer drugs demonstrates a concerted effort to enhance affordability and access to vital treatments. Concurrently, legislative proposals advocating for free cancer treatment for middle-class households underscore the government's commitment to equitable healthcare provision. Moreover, the development of Cervavac, India's indigenous vaccine against cervical cancer, showcases proactive strides in preventive healthcare. These initiatives reflect a holistic approach towards bolstering cancer care infrastructure and addressing the evolving healthcare landscape.

Challenges

High Cost of Treatment

The high cost of treatment serves as a significant constraint on the growth of the India oncology drugs market. Affordability issues limit patient access to life-saving medications, hindering market expansion. Additionally, this financial burden impacts healthcare infrastructure, restricting investments in research, development, and distribution of oncology drugs. The resultant lack of widespread availability exacerbates the challenge of addressing the rising cancer burden in the country. Efforts to mitigate these cost barriers through regulatory measures and government initiatives are crucial for fostering market growth and ensuring equitable access to cancer care across India.

India Oncology Drugs Market

Segmental Coverage

India Oncology Drugs Market – By Drug Class

By drug class, the India Oncology Drugs Market is divided into Cytotoxic Drugs, Targeted Drugs, and Hormonal Drugs segments. The targeted drugs holds the highest share in the India Oncology Drugs Market by drug class. Targeted therapies aim to disrupt particular molecules crucial for the advancement and proliferation of cancer cells, offering a reduced risk of side effects compared to conventional chemotherapy. Advancements in understanding the molecular and genetic changes underlying tumor formation have facilitated the development of various targeted treatments. Notable breakthroughs include cancer immunotherapies, PARP inhibitors effective against ovarian and breast cancers, BCR-ABL inhibitors for chronic myeloid leukemia, and treatments targeting EGFR and ALK mutations in lung cancer. Recognizing their high precision and market viability, major pharmaceutical firms have made substantial investments in the research and development of targeted drugs.

India Oncology Drugs Market – By Therapy Type

Based on therapy type, the India Oncology Drugs Market is divided into Chemotherapy, Targeted Therapy, and Immunotherapy segments. The immunotherapy segment is expected to hold the highest share in the India Oncology Drugs Market by therapy type during the forecast period. Immunotherapy, a promising cancer treatment, activates the body's immune system to combat the disease, showing efficacy primarily in advanced stage patients. Its suitability varies based on cancer type and patient condition. Effective against diverse cancers like lung, kidney, bladder, melanoma, cervical, and lymphoma, a study in India revealed nivolumab's (Opdivo) low doses prolonged survival in advanced head and neck cancer patients at 6% of Western dosages, potentially reducing costs. Clinical trials combining minimal nivolumab doses with standard head and neck cancer treatments in India hint at improving patient outcomes. Amid rising cancer rates, innovations aimed at enhancing cancer care contribute to market growth.

India Oncology Drugs Market – By Indication

On the basis of indication, the India Oncology Drugs Market is divided into Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, and Prostate Cancer segments. The breast cancer segment holds the highest share in the India Oncology Drugs Market by indication. It is primarily due to its prevalence as the most diagnosed cancer among Indian women. Improved awareness campaigns and healthcare infrastructure have led to early detection rates. Advanced treatment options like targeted therapies and hormonal treatments further contribute to the demand for oncology drugs specific to breast cancer treatment, solidifying its position as the leading indication segment in the market.

India Oncology Drugs Market – By Dosage Form

By end user, the India Oncology Drugs Market is divided into Solid, Liquid, and Injectable segments.

India Oncology Drugs Market – By Distribution Channel

Based on distribution channel, the India Oncology Drugs Market is divided into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies segments. The hospital pharmacies segment holds the highest share in the India Oncology Drugs Market by distribution channel. Hospitals serve as primary centers for cancer diagnosis, treatment, and management, resulting in significant demand for oncology drugs. Hospital pharmacies ensure immediate access to essential medications, meeting the urgent needs of cancer patients. Moreover, hospitals often benefit from economies of scale and bulk purchasing, enabling cost-effective procurement of oncology drugs. Overall, the hospital pharmacies segment plays a pivotal role in facilitating the availability and distribution of oncology drugs across India.

India Oncology Drugs Market – By Region

Geographically, the India Oncology Drugs Market is divided into North India, South India, East India, and West India regions.

Competitive Landscape

Major players operating in India Oncology Drugs Market include Roche, Novartis Oncology, Celgene, Johnson & Johnson, AbbVie, Arlak Biotech, Bristol-Myers Squibb, Pfizer Inc, Merck & Co, Eli Lilly and Company, AstraZeneca plc, Bayer AG, Amgen Inc, Getwell Pharma, and Intelicure Lifesciences. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Recent Developments

• In January 2023 - Sun Pharmaceutical Industries Ltd launched Palenotm, an anti-cancer medication, in India through one of its subsidiaries. Palenotm, available in 75 mg, 100 mg, and 125 mg variants, aims to address the needs of patients battling advanced breast cancer.

Scope of the Report

By Drug Class

• Cytotoxic Drugs

• Targeted Drugs

• Hormonal Drugs

By Therapy Type

• Chemotherapy

• Targeted Therapy

• Immunotherapy

By Indication

• Lung Cancer

• Stomach Cancer

• Colorectal Cancer

• Breast Cancer

• Prostate Cancer

By Dosage Form

• Solid

• Liquid

• Injectable

By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

By Region

• North India

• South India

• East India

• West India

1. Research Framework
   1. Research Objective
   2. Product Overview
   3. Market Segmentation
2. Executive Summary
3. India Oncology Drugs Market Insights
   1. Industry Value Chain Analysis
   2. DROC Analysis
      1. Growth Drivers
         1. Rising cancer burden
         2. Growing awareness about cancer
         3. Government initiatives for improving cancer care
         4. Increasing adoption of advanced technologies like minimally invasive surgeries
      2. Restraints
         1. High cost of treatment
         2. Limited availability of cancer care facilities, especially in rural areas
         3. Shortage of qualified oncologists and other healthcare professionals specializing in cancer treatment
      3. Opportunities
         1. Strong demand for cost-effective oncology drugs in India
         2. Increasing number of cancer health insurances
      4. Challenges
         1. Lack of early detection awareness
         2. Stringent regulation and patent expiry
   3. Technological Advancements/Recent Developments
   4. Regulatory Framework
   5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
4. India Oncology Drugs Market: Pricing Analysis
5. India Oncology Drugs Market: Marketing Strategies
6. India Oncology Drugs Market Overview
   1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
   2. Market Share & Forecast
      1. By Drug Class
         1. Cytotoxic Drugs
         2.  Targeted Drugs
         3. Hormonal Drugs
         4.  Others
      2. By Therapy Type
         1. Chemotherapy
         2.  Targeted Therapy
         3.  Immunotherapy
      3. By Indication
         1. Lung Cancer
         2. Stomach Cancer
         3.  Colorectal Cancer
         4. Breast Cancer
         5.  Prostate Cancer
         6.  Others
      4. By Dosage Form
         1. Solid
         2. Liquid
         3. Injectable
      5. By Distribution Channel
         1. Hospital Pharmacies
         2.  Retail Pharmacies
         3.  Online Pharmacies
      6. By Region
         1. North India
         2. South India
         3. East India
         4. West India
7. North India Oncology Drugs Market Overview
   1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
   2. Market Share & Forecast
      1. By Drug Class
      2. By Therapy Type
      3. By Indication
      4. By Dosage Form
      5. By Distribution Channel
8. South India Oncology Drugs Market Overview
   1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
   2. Market Share & Forecast
      1. By Drug Class
      2. By Therapy Type
      3. By Indication
      4. By Dosage Form
      5. By Distribution Channel
9. East India Oncology Drugs Market Overview
   1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
   2. Market Share & Forecast
      1. By Drug Class
      2. By Therapy Type
      3. By Indication
      4. By Dosage Form
      5. By Distribution Channel
10. West India Oncology Drugs Market Overview
    1. Market Size & Forecast, 2019–2030
       1. By Value (USD Billion)
    2. Market Share & Forecast
       1. By Drug Class
       2. By Therapy Type
       3. By Indication
       4. By Dosage Form
       5. By Distribution Channel
11. India Oncology Drugs Market: Import & Export
12. Competitive Landscape
    1. List of Key Players and Their Offerings
    2. India Oncology Drugs Company Market Share Analysis, 2023
    3. Competitive Benchmarking, By Operating Parameters
    4. Key Strategic Development (Mergers, Acquisitions, Partnerships, etc.)
13. Impact of Geopolitical Tensions in India Oncology Drugs Market
14. Company Profiles (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)
    1. Roche
    2. Novartis Oncology
    3. Celgene
    4. Johnson & Johnson
    5. AbbVie
    6. Arlak Biotech
    7.  Bristol-Myers Squibb
    8. Pfizer Inc
    9. Merck & Co
    10. Eli Lilly and Company
    11.  AstraZeneca plc
    12. Bayer AG
    13. Amgen Inc
    14. Getwell Pharma
    15. Intelicure Lifesciences
    16. Other Prominent Players
15. Key Strategic Recommendations
16. Research Methodology
    1. Qualitative Research
       1. Primary & Secondary Research
    2. Quantitative Research
    3. Market Breakdown & Data Triangulation
       1. Secondary Research
       2. Primary Research
    4. Breakdown of Primary Research Respondents, By Region
    5. Assumption & Limitation

* Financial information of non-listed companies will be provided as per availability

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable

List of Figures

Figure 1       India Oncology Drugs Market Segmentation

Figure 2       India Oncology Drugs Market Value Chain Analysis

Figure 3       Company Market Share Analysis, 2023

Figure 4       India Oncology Drugs Market Size, By Value (USD Billion), 2019–2030

Figure 5       India Oncology Drugs Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 6       India Oncology Drugs Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 7       India Oncology Drugs Market Share, By Indication, By Value (USD Billion), 2019–2030

Figure 8       India Oncology Drugs Market Share, By Dosage Form, By Value (USD Billion), 2019–2030

Figure 9       India Oncology Drugs Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 10     India Oncology Drugs Market Share, By Region, By Value (USD Billion), 2019–2030

Figure 11     North India Oncology Drugs Market Size, By Value (USD Billion), 2019–2030

Figure 12     North India Oncology Drugs Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 13     North India Oncology Drugs Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 14     North India Oncology Drugs Market Share, By Indication, By Value (USD Billion), 2019–2030

Figure 15     North India Oncology Drugs Market Share, By Dosage Form, By Value (USD Billion), 2019–2030

Figure 16     North India Oncology Drugs Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 17     South India Oncology Drugs Market Size, By Value (USD Billion), 2019–2030

Figure 18     South India Oncology Drugs Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 19     South India Oncology Drugs Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 20     South India Oncology Drugs Market Share, By Indication, By Value (USD Billion), 2019–2030

Figure 21     South India Oncology Drugs Market Share, By Dosage Form, By Value (USD Billion), 2019–2030

Figure 22     India Oncology Drugs Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 23     East India Oncology Drugs Market Size, By Value (USD Billion), 2019–2030

Figure 24     East India Oncology Drugs Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 25     East India Oncology Drugs Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 26     East India Oncology Drugs Market Share, By Indication, By Value (USD Billion), 2019–2030

Figure 27     East India Oncology Drugs Market Share, By Dosage Form, By Value (USD Billion), 2019–2030

Figure 28     East India Oncology Drugs Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 29     West India Oncology Drugs Market Size, By Value (USD Billion), 2019–2030

Figure 30     West India Oncology Drugs Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 31     West India Oncology Drugs Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 32     West India Oncology Drugs Market Share, By Indication, By Value (USD Billion), 2019–2030

Figure 33     West India Oncology Drugs Market Share, By Dosage Form, By Value (USD Billion), 2019–2030

Figure 34     West India Oncology Drugs Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

List of Tables

Table 1      India Oncology Drugs Market Size, By Value (USD Billion), 2019–2030

Table 2      India Oncology Drugs Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Table 3      India Oncology Drugs Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Table 4      India Oncology Drugs Market Share, By Indication, By Value (USD Billion), 2019–2030

Table 5      India Oncology Drugs Market Share, By Dosage Form, By Value (USD Billion), 2019–2030

Table 6      India Oncology Drugs Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 7      India Oncology Drugs Market Share, By Region, By Value (USD Billion), 2019–2030

Table 8      North India Oncology Drugs Market Size, By Value (USD Billion), 2019–2030

Table 9      North India Oncology Drugs Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Table 10    North India Oncology Drugs Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Table 11    North India Oncology Drugs Market Share, By Indication, By Value (USD Billion), 2019–2030

Table 12    North India Oncology Drugs Market Share, By Dosage Form, By Value (USD Billion), 2019–2030

Table 13    North India Oncology Drugs Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 14    South India Oncology Drugs Market Size, By Value (USD Billion), 2019–2030

Table 15    South India Oncology Drugs Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Table 16    South India Oncology Drugs Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Table 17    South India Oncology Drugs Market Share, By Indication, By Value (USD Billion), 2019–2030

Table 18    South India Oncology Drugs Market Share, By Dosage Form, By Value (USD Billion), 2019–2030

Table 19    South India Oncology Drugs Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 20    East India Oncology Drugs Market Size, By Value (USD Billion), 2019–2030

Table 21    East India Oncology Drugs Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Table 22    East India Oncology Drugs Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Table 23    East India Oncology Drugs Market Share, By Indication, By Value (USD Billion), 2019–2030

Table 24    East India Oncology Drugs Market Share, By Dosage Form, By Value (USD Billion), 2019–2030

Table 25    East India Oncology Drugs Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 26    West India Oncology Drugs Market Size, By Value (USD Billion), 2019–2030

Table 27    West India Oncology Drugs Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Table 28    West India Oncology Drugs Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Table 29    West India Oncology Drugs Market Share, By Indication, By Value (USD Billion), 2019–2030

Table 30    West India Oncology Drugs Market Share, By Dosage Form, By Value (USD Billion), 2019–2030

Table 31    West India Oncology Drugs Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 32    Roche Company Overview

Table 33    Roche Company Overview

Table 34    Novartis Oncology Company Overview

Table 35    Novartis Oncology Company Overview

Table 36    Celgene Company Overview

Table 37    Celgene Company Overview

Table 38    Johnson & Johnson Company Overview

Table 39    Johnson & Johnson Company Overview

Table 40    AbbVie Company Overview

Table 41    AbbVie Company Overview

Table 42    Arlak Biotech Company Overview

Table 43    Arlak Biotech Company Overview

Table 44    Bristol-Myers Squibb Company Overview

Table 45    Bristol-Myers Squibb Company Overview

Table 46    Pfizer Inc Company Overview

Table 47    Pfizer Inc Company Overview

Table 48    Merck & Co Company Overview

Table 49    Merck & Co Company Overview

Table 50    Eli Lilly and Company Overview

Table 51    Eli Lilly and Company Overview

Table 52    AstraZeneca plc Company Overview

Table 53    AstraZeneca plc Company Overview

Table 54    Bayer AG Company Overview

Table 55    Bayer AG Company Overview

Table 56    Amgen Inc Company Overview

Table 57    Amgen Inc Company Overview

Table 58    Getwell Pharma Company Overview

Table 59    Getwell Pharma Company Overview

Table 60    Intelicure Lifesciences Company Overview

Table 61    Intelicure Lifesciences Company Overview